Health Care·Biotechnology·$161.9B
Gilead Sciences Inc (GILD) is a biotechnology company focused on developing innovative medicines, particularly in the areas of HIV, liver diseases, and oncology. With a market cap of $166 billion, Gilead plays a crucial role in the healthcare sector, addressing significant medical needs and contributing to advancements in treatment options.
Earnings Per Share (EPS)
EPS is a key indicator of the company's profitability and is closely watched by investors.
Revenue
Revenue figures provide insight into the company's overall sales performance and market demand for its products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
8Q
EPS Beat Rate
100%
Avg EPS Surprise
+12.39%
Avg Stock Reaction
-0.18%
In Q4 2025, Gilead reported an EPS of $1.86, exceeding expectations by nearly 2%. The company did not provide revenue figures, but the positive EPS surprise indicates strong operational performance.
Management Promises & Guidance
Analysts expect Gilead to report an EPS of $1.91 and revenue of $6.9 billion for Q1 2026, reflecting steady growth in its core therapeutic areas.
Bull Case
If Gilead can exceed EPS expectations and show strong revenue growth, it could signal robust demand for its products, potentially driving the stock higher.
Bear Case
Conversely, if Gilead falls short of expectations, particularly in revenue, it may raise concerns about market competition and product demand, leading to a negative reaction.
Earnings Per Share (EPS)
$1.91EPS is a key indicator of the company's profitability and is closely watched by investors.
Revenue
$6.9BRevenue figures provide insight into the company's overall sales performance and market demand for its products.
The print will turn on these two things.
Q1
Will Gilead's EPS exceed the consensus estimate of $1.91?
A higher EPS could indicate stronger profitability and operational efficiency, which would be positively received by the market.
Q2
What revenue figures will Gilead report, and how do they compare to the expected $6.9 billion?
Revenue performance is critical for assessing market demand and the success of Gilead's product portfolio.
Why consensus could be wrong
The Street may underestimate Gilead's ability to leverage its recent product innovations, which could drive higher-than-expected revenue growth.
Supporting Evidence
Gilead has a history of exceeding EPS estimates, as seen in the last few quarters.
The options market is pricing a 5% move, which may be conservative given Gilead's recent performance.
Analysts may not fully account for the potential impact of new product launches on revenue.
Key Risk
If Gilead's new treatments show significant uptake, it could lead to a substantial revenue surprise.
Pre-commit to what would confirm each case.
The market is closely watching Gilead's ability to meet or exceed these expectations, as they will significantly influence investor sentiment.
Bull Confirmed If
An EPS of $2.06 or higher, along with revenue exceeding $7.1 billion, would confirm a strong bull case.
Bear Confirmed If
An EPS below $1.74 and revenue under $6.8 billion would suggest a bearish outlook.
Implied Move
±5%
Historical Avg
±1.3%
The options market is pricing in a potential move of 5% in either direction following the earnings report.
Options are pricing ±5.0% while GILD has averaged ±1.3% over the last 8 prints — setup is pricing rich.
Cross-company pattern from 30 similar setups.
Prior-quarter beat setup in Health Care
n=30Fade rate: 16 of 29 (55%)
This setup has occurred 30 times across Health Care in the last 2 years. 16 of 29 faded and 13 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 4.1%, with a raw directional average of -0.7% (modestly negative historical bias).
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Gilead beats expectations, history suggests the stock could rise by an average of 4.1%, confirming strong demand and operational success.
In-Line / Cautious
An in-line report may lead to a muted reaction, as investors weigh management's commentary on future growth prospects.
Miss
A miss on earnings could lead to a decline, with historical patterns indicating an average drop of around 0.7%.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026